Drug intelligence / Profile preview

NST-0025

Development stage: Unknown
Lead developer: Novasenta
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

NST-0025 is a monoclonal antibody drug developed by Novasenta. It functions as an immunomodulator, meaning it modulates the immune system's activity. The specific molecular target and disease indications have not been disclosed publicly as of April 2025. The drug is in early-stage development and has not yet reached clinical approval or advanced clinical trial phases[1].

Beyond the preview

Go deeper on NST-0025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NST-0025.

Explore the full profile